Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr;37(3):561-571.
doi: 10.1007/s40620-023-01853-z. Epub 2024 Jan 16.

Outcomes and management of kidney transplant recipients with Fabry disease: a review

Bo Yu  1 , Mohamed G Atta  2 , Daniel C Brennan  2   3 , Sam Kant  4   5
Affiliations
Review

Outcomes and management of kidney transplant recipients with Fabry disease: a review

Bo Yu et al. J Nephrol. 2024 Apr.

Abstract

Fabry disease is an X-linked inheritable lysosomal storage disease caused by various mutations of the galactosidase α gene resulting in α-galactosidase deficiency. Chronic kidney disease (CKD) is one of the most significant consequences of Fabry disease, with risk of end-stage kidney disease (ESKD) in this population. Like for other patients with ESKD, kidney transplant is the optimal treatment for Fabry disease patients with ESKD. However, enzyme replacement therapy and newer Fabry disease treatments remain important to mitigate other end organ damage such as cardiomyopathy post transplantation. This review is a primer on Fabry disease, which examines the outcomes of disease in the context of kidney transplant prior to, and during, the enzyme replacement treatment era, medical treatment of kidney transplant recipients with Fabry disease, and progress in screening studies.

Keywords: Enzyme replacement therapy; Fabry disease; Fabry nephropathy; Kidney transplant; Outcome.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Klingelhofer D, Braun M, Seeger-Zybok RK, Quarcoo D, Bruggmann D, Groneberg DA (2020) Global research on Fabry’s disease: demands for a rare disease. Mol Genet Genomic Med 8(9):e1163 - PubMed - PMC - DOI
    1. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L (1967) Enzymatic defect in Fabry’s disease Ceramidetrihexosidase deficiency. N Engl J Med 276(21):1163–1167 - PubMed - DOI
    1. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski G, Packman S, Wilcox WR (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138(4):338–346 - PubMed - DOI
    1. Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, Eng C, Hopkin RJ, Laney D, Linhart A et al (2018) Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab 123(4):416–427 - PubMed - DOI
    1. Doheny D, Srinivasan R, Pagant S, Chen B, Yasuda M, Desnick RJ (2018) Fabry Disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995–2017. J Med Genet 55(4):261–268 - PubMed - DOI

MeSH terms

Substances

LinkOut - more resources